查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922955

全磁浮心室辅助装置市场按帮浦植入部位、年龄层、保险覆盖范围、应用和最终用户划分－2026年至2032年全球预测

Fully MagLev Ventricular Assist Device Market by Pump Placement, Age Group, Insurance Coverage Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年全磁浮心室辅助装置市值为 6.4567 亿美元，预计到 2026 年将增长至 7.3549 亿美元，年复合增长率为 15.67%，到 2032 年将达到 17.8913 亿美元。

主要市场统计数据
基准年 2025 6.4567亿美元
预计年份：2026年 7.3549亿美元
预测年份：2032年 17.8913亿美元
复合年增长率 (%) 15.67%

本文精彩概述了新一代磁浮心室辅助装置如何改变临床实务模式和医疗服务模式。

机械循环支援领域正经历快速变革时期，这主要得益于技术进步和临床实践的不断发展。全磁浮心室辅助装置代表了数十年来泵浦机械、材料科学和临床整合方面不断改进的结晶。这些装置旨在最大限度地减少血流动力学压力，降低血栓风险，延长装置使用寿命，同时实现微创手术，并提高患者的生活品质。它们的出现不仅是技术的渐进式发展，更是对长期支持的期望的重新定义，并拓展了关于復健过渡、移植过渡和最终治疗方案的临床讨论。

磁浮泵动态技术的进步、数位化整合以及不断发展的临床通讯协定，如何共同重塑其应用管道和医疗服务模式

随着技术、临床证据和医疗系统能力的融合，心室辅助性治疗领域正经历变革性的转变。磁浮泵可减少摩擦和机械磨损，从而直接提高装置的耐用性并降低装置相关溶血的发生率。这项技术进步正在推动临床通讯协定的变革，外科医生和心臟团队正在重新思考植入时机、抗凝血方案和门诊管理途径，以优化长期疗效。同时，微创植入技术和更短的加护病房住院时间也日益普及，从而重塑了医院资源的利用方式和病患的復原过程。

2025年美国新贸易措施的综合影响将波及整个增值分销（VAD）生态系统的供应链韧性、采购经济性和战略製造决策。

2025年推出的关税和贸易政策变化进一步加剧了现有供应链的脆弱性，迫使心室辅助装置生态系统中的各相关人员重新思考其筹资策略。零件和成品进口关税的提高正在对医疗保健系统的单位成本、采购週期和资本配置决策产生连锁反应。为此，製造商正在重新评估其全球运营，并加快近岸外包和本地化生产的步伐，以降低跨境贸易波动带来的风险，并维持可预测的利润率。

深入洞察应用程式、终端用户环境、泵浦的位置、患者人口统计特征和保险计划如何共同决定产品和市场策略。

特定细分市场的趋势正在潜移默化地影响全磁浮设备的临床和商业策略。在考虑应用情境时，装置设计和管道整合必须涵盖从过渡治疗到復健、追踪观察移植和最终治疗的整个过程。特别是择期移植追踪观察，由于临床终点和手术全期需求不同，需要针对长期和短期使用制定差异化的策略。就终端使用者而言，门诊中心需要简化的门诊管理功能和追踪通讯协定，而心臟照护中心则强调急性期和亚急性期照护之间的工作流程整合。从社区医院到三级医疗中心，各类医院都需要可扩展的解决方案，以适应不同的患者数量、外科医生经验水平和重症监护资源。

监管多样性、基础设施差异以及关键区域的支付方生态系统如何塑造磁浮辅助装置（VAD）的不同应用管道

区域趋势对全磁浮心室辅助装置的临床导入管道、监管反应和商业性策略有显着影响。在美洲，先进的临床基础设施和集中式卓越中心支持新技术快速应用，但分散的支付体系和各州不同的采购政策要求制定量身定制的报销策略并提供强有力的卫生经济学证据。在欧洲、中东和非洲，监管环境各异，集中核准和各国不同的报销谈判给相关人员带来了挑战。这为分阶段市场进入和区域性定制的临床试验设计提供了机会，以证明其相对价值。

为了确保可持续的竞争优势，将设备创新、临床证据产生和服务导向商业化相结合的策略竞争定位和合作管道至关重要。

全磁浮心室辅助装置领域的竞争格局呈现出多元化的特点：既有不断拓展产品线的成熟医疗设备製造商，也有凭藉核心泵浦感测器技术进行创新的敏捷型Start-Ups，还有为大规模生产提供支援的专业契约製造。市场领导往往注重患者的整体管理，而不仅仅是设备硬件，并充分利用其深厚的临床关係、广泛的术后护理网络和整合服务。新参与企业则通常专注于设计创新，例如减少抗凝血药物的使用或简化控制器，并寻求策略性的临床合作伙伴关係，以检验产品在实际应用中的表现。

为製造商和医疗领导者提供实际有效的步骤，以将磁浮设备的创新转化为持续的临床应用和商业性成功。

行业领导者应优先考虑一系列综合倡议，以将技术潜力转化为持续的临床和商业性成功。首先，产品开发必须与明确的临床应用相契合，确保设计功能能够满足各种需求，例如復健过渡、移植过渡、短期和长期应用以及最终治疗。同时，投资临床医生培训和卓越中心计画将加速安全应用，优化早期治疗效果，并建立更广泛的医疗保险报销所需的临床证据基础。

我们采用透明、多维度的研究途径，整合临床访谈、真实世界数据和监管审查，以检验研究结果并识别实际限制因素。

本报告的研究结合了结构化的初级和二级研究方法，旨在确保研究结果的可靠性和多方验证。初级资料收集包括对心臟病学和心胸外科领域的关键高管、急诊医院的采购和供应链总监以及医疗设备製造商和服务供应商的高级商业领导进行深度访谈。此外，还透过专家圆桌会议和咨询小组来检验新出现的主题，并揭示实际应用中遇到的挑战。

这是一份简洁、全面且全面的分析报告，重点阐述了医疗设备创新、证据产生和系统层级策略之间的相互依存关係，而这些关係对于实现广​​泛的临床影响至关重要。

全磁浮心室辅助装置代表了机械循环支援领域的突破，其临床效益远超泵性能的提升。随着技术的日趋成熟，各环节——包括产品开发、临床证据产生、供应链韧性以及与支付方的合作——的协调策略对于这些装置顺利应用于常规临床实践至关重要。相关人员应认识到，装置性能本身并不能保证其被广泛采用；整合的服务模式、以患者为中心的、可证实的疗效以及切实可行的报销策略同样重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 全磁浮心室辅助装置市场（依泵浦安装位置划分）

  • 体外
  • 内式
    • 腹部
    • 胸部
  • 外部援助

9. 依年龄组别分類的全磁浮心室辅助装置市场

  • 成人
  • 儿童

第十章 保险覆盖范围下的全磁浮心室辅助装置市场

  • 私人的
  • 民众

第十一章 全磁浮心室辅助装置市场（依应用划分）

  • 通往復健的桥樑
  • 移植桥樑
    • 长期
    • 短期
  • 最终治疗

第十二章 全磁浮心室辅助装置市场（依最终用户划分）

  • 门诊治疗中心
  • 心臟护理中心
  • 医院
    • 区域医疗设施
    • 三级医疗机构

第十三章 各地区全磁浮心室辅助装置市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 全磁浮心室辅助装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国全磁浮心室辅助装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国全磁浮心室辅助装置市场

第十七章 中国全磁浮心室辅助装置市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • CH Biomedical Co., Ltd.
  • CorWave SA
  • Evaheart Inc.
  • Jarvik Heart Inc.
  • Leviticus Cardio LLC
  • Medtronic plc
  • ReliantHeart Inc.
  • Shenzhen Core Medical Technology Co., Ltd.
  • Suzhou Tongxin Medical Devices Co., Ltd.
  • SynCardia Systems LLC
  • Teleflex Incorporated
Product Code: MRR-867BED9A9E80

The Fully MagLev Ventricular Assist Device Market was valued at USD 645.67 million in 2025 and is projected to grow to USD 735.49 million in 2026, with a CAGR of 15.67%, reaching USD 1,789.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 645.67 million
Estimated Year [2026] USD 735.49 million
Forecast Year [2032] USD 1,789.13 million
CAGR (%) 15.67%

An engaging overview of how next-generation magnetic levitation ventricular assist devices are altering clinical practice paradigms and healthcare delivery models

The field of mechanical circulatory support has entered a phase of rapid transition, driven by technological advances and evolving clinical practice. Fully magnetically levitated ventricular assist devices represent a culmination of decades-long refinement in pump mechanics, materials science, and clinical integration. These devices are engineered to minimize blood trauma, reduce thrombosis risk, and extend device longevity while enabling less invasive surgical approaches and improved patient quality of life. Their emergence is not merely incremental; it redefines expectations for long-term support and expands the clinical conversation around options for bridge to recovery, bridge to transplant, and destination therapy.

Clinicians and healthcare systems are assessing these systems not only for their hemodynamic performance but also for their implications across care pathways. Advances in materials and pump dynamics have influenced perioperative management, anticoagulation strategies, and outpatient follow-up models. Concurrently, digital monitoring and remote patient management capabilities are increasingly integrated into device ecosystems, enabling proactive complication detection and more reliable longitudinal care. As a result, stakeholders from clinicians and hospital administrators to payers and device manufacturers are re-evaluating protocols for patient selection, training, and infrastructure investment. This introduction frames the broader landscape and sets the stage for a detailed examination of market shifts, segmentation dynamics, regional differences, and strategic priorities that follow.

How technical refinements in maglev pump mechanics, digital integration, and evolving clinical protocols are jointly reshaping adoption pathways and care delivery

The landscape for ventricular assist therapy is undergoing transformative shifts as technology, clinical evidence, and health system capabilities converge. Magnetically levitated pumps have reduced friction and mechanical wear, which directly influences device durability and lowers the incidence of device-related hemolysis. This technical progress is catalyzing changes in clinical protocols, with surgeons and heart teams reconsidering implantation timing, anticoagulation regimens, and outpatient management pathways to optimize long-term outcomes. At the same time, minimally invasive implantation techniques and shorter intensive care unit stays are progressively feasible, reshaping hospital resource utilization and patient recovery trajectories.

Concurrently, digital health integration has accelerated, with telemonitoring and remote diagnostics providing richer streams of patient data that inform adherence, early complication detection, and tailored therapy adjustments. These capabilities support models of decentralized care that can extend specialist oversight into ambulatory centers and community hospitals. Regulatory environments are also adapting, with agencies emphasizing robust post-market surveillance and real-world evidence to validate long-term safety and performance. Moreover, procurement decision-making is increasingly influenced by total cost of care considerations and payer engagement, prompting manufacturers to design solutions that align clinical value with economic sustainability. Together, these shifts underscore a transition from isolated device adoption toward system-level integration, where device performance, care delivery models, and reimbursement strategies must co-evolve to create sustained clinical and commercial success.

The aggregate influence of new US trade measures in 2025 on supply chain resilience, procurement economics, and strategic manufacturing decisions across the VAD ecosystem

The introduction of tariffs and trade policy changes in 2025 has compounded preexisting supply chain fragilities and compelled stakeholders to rethink sourcing strategies across the ventricular assist device ecosystem. Increased import duties on components and finished devices have cascading effects on unit pricing, procurement cycles, and capital allocation decisions within health systems. In response, manufacturers are revisiting their global operations, accelerating nearshoring and regional manufacturing initiatives to mitigate exposure to cross-border trade volatility and to preserve predictable margins.

Moreover, tariffs influence the economics of aftermarket services and spare parts distribution, prompting healthcare providers to reconsider inventory strategies and to seek contractual assurances on service-level agreements. As a result, stakeholders are placing higher value on transparent cost structures and predictable logistics. Policy shifts also affect investment flows, where heightened import costs can delay new product introductions into certain markets and incentivize domestic partnering or licensing arrangements. Consequently, device developers and suppliers are placing greater emphasis on resilient procurement models, flexible manufacturing footprints, and strategic partnerships to maintain supply continuity and to support consistent clinical access despite an increasingly complex international trade environment.

Actionable insights into how application, end user environments, pump placement, patient age groups, and insurance frameworks jointly dictate product and market strategies

Segment-specific dynamics are shaping both clinical and commercial strategies for fully magnetically levitated devices in nuanced ways. When considering application, device design and pathway integration must accommodate the full continuum from bridge to recovery to bridge to transplant and destination therapy, with the bridge to transplant indication requiring differentiated strategies for long-term and short-term use given divergent clinical endpoints and perioperative demands. In terms of end users, ambulatory centres demand streamlined outpatient management features and simplified follow-up protocols, while cardiac care centres emphasize integrated acute and subacute workflows; hospitals, whether community or tertiary, require scalable solutions that address varied volumes, surgeon experience, and intensive care resources.

Pump placement introduces further complexity: extracorporeal options prioritize rapid deployment and temporary support, paracorporeal solutions balance mobility with durability for select cases, and intracorporeal devices-whether abdominal or thoracic-present distinct surgical approaches, imaging considerations, and patient comfort profiles. Age group segmentation drives both design decisions and clinical pathways, as adult patients and pediatric cohorts differ substantially in anatomical constraints, growth considerations, and long-term management needs. Finally, insurance coverage type shapes access and adoption; private coverage often correlates with faster device uptake and broader reimbursement for novel applications, whereas public coverage frameworks emphasize cost-effectiveness and outcome evidence, requiring manufacturers to demonstrate measurable clinical benefits and reliable longitudinal performance. Together, these segmentation layers require integrated product development and market access strategies that align device capabilities with the clinical realities and payer expectations of each segment.

How regional regulatory diversity, infrastructure variance, and payer ecosystems across key geographies shape differentiated adoption pathways for maglev VADs

Regional dynamics are strongly influential in determining clinical adoption pathways, regulatory navigation, and commercial approaches for fully magnetically levitated ventricular assist systems. In the Americas, advanced clinical infrastructure and concentrated centers of excellence support rapid uptake of novel technologies, yet fragmented payer systems and varying state-level procurement policies require tailored reimbursement strategies and robust health economic evidence. Transitioning to Europe, Middle East & Africa, stakeholders face a heterogeneous regulatory landscape, where centralized approvals coexist with country-specific reimbursement negotiations, creating opportunities for staged market entry and region-specific clinical trial design to demonstrate comparative value.

In the Asia-Pacific region, rising cardiovascular disease burden, expanding tertiary care networks, and increasing local manufacturing capacity combine to create a dynamic environment for uptake. However, adoption trajectories differ between high-income urban centers and more resource-constrained settings, prompting manufacturers to consider modular product offerings and scalable service models. Across all regions, clinician training, post-market surveillance, and supply chain localization remain critical enablers of adoption. Moreover, regional reimbursement pathways and procurement norms drive the prioritization of evidence generation and value communication, necessitating differentiated market entry plans that respect local health system structures and patient access imperatives.

Strategic competitive positioning and collaborative pathways that combine device innovation, clinical evidence generation, and service-oriented commercialization for sustained advantage

Competitive dynamics in the fully magnetically levitated ventricular assist device arena are characterized by a mix of established medical device companies extending portfolios, agile startups innovating on core pump and sensor technologies, and specialized contract manufacturers supporting scale-up. Market leaders tend to leverage deep clinical relationships, broad aftercare networks, and integrated service offerings to differentiate on total patient management rather than on device hardware alone. New entrants frequently focus on disruptive aspects of design-such as reduced anticoagulation requirements or simplified controllers-and seek strategic clinical partnerships to validate real-world performance.

Intellectual property and clinical evidence are central competitive levers, with firms investing in multicenter registries, investigator-initiated studies, and outcomes research to demonstrate superior safety and quality-of-life impacts. In parallel, alliances with surgical societies, training consortia, and digital health vendors are becoming more common as companies aim to deliver end-to-end solutions that include remote monitoring and predictive maintenance. Supply chain partnerships and regional manufacturing agreements also play a critical role in competitive positioning, enabling faster time-to-market and localized service support. Ultimately, successful companies will harmonize technical innovation with robust clinical data generation, scalable manufacturing, and a service-oriented commercial approach to meet the complex needs of patients and providers.

Practical, high-impact steps for manufacturers and healthcare leaders to translate MagLev device innovation into sustained clinical adoption and commercial success

Industry leaders should prioritize a set of integrated actions to convert technological promise into durable clinical and commercial success. First, aligning product development with distinct clinical applications-ensuring that design features meet the divergent needs of bridge to recovery, bridge to transplant short-term and long-term use cases, and destination therapy-will be essential. Parallel investments in clinician training and center-of-excellence programs will accelerate safe adoption and optimize early outcomes, thereby building the clinical evidence base required for broader reimbursement.

Second, strengthening supply chain resilience through regional manufacturing, dual sourcing of critical components, and strategic inventory planning can mitigate trade-related disruptions and reduce time-to-service for critical parts. Third, engaging payers proactively to articulate value propositions that reflect total cost of care and patient-centered outcomes will facilitate constructive reimbursement discussions and support access. Fourth, integrating digital monitoring and predictive analytics into device ecosystems will enhance remote care capabilities and help differentiate offerings on service performance. Finally, forging partnerships with surgical societies, patient advocacy groups, and post-market data consortia will accelerate evidence generation and trust in novel therapies. Taken together, these measures create an interdependent strategy that balances innovation, operational resilience, and payer-aligned value demonstration.

A transparent, multi-source research approach integrating clinical interviews, real-world evidence, and regulatory review to validate insights and identify practical constraints

The research underpinning this report combines structured primary and secondary methodologies designed to ensure robust, triangulated insights. Primary data collection included in-depth interviews with clinical key opinion leaders across cardiology and cardiothoracic surgery, procurement and supply chain executives from acute care institutions, and senior commercial leaders from device manufacturers and service providers. These qualitative engagements were complemented by expert roundtables and advisory panels to validate emergent themes and to surface practical implementation challenges experienced in real-world settings.

Secondary research encompassed a thorough review of peer-reviewed clinical literature, device registries, regulatory filings, and technology white papers to contextualize device performance, safety profiles, and procedural trends. Real-world evidence from post-market surveillance reports and health system case studies informed understanding of utilization patterns and care pathway adaptations. Data synthesis relied on methodological triangulation, cross-referencing multiple evidence sources to validate findings and to identify gaps. Recognizing inherent limitations, including variability in reporting standards and evolving regulatory requirements, the approach emphasizes transparency and confidence grading for key insights to support informed decision-making by stakeholders.

A succinct synthesis highlighting the interdependence of device innovation, evidence generation, and system-level strategies necessary to realize widespread clinical impact

Fully magnetically levitated ventricular assist devices represent a pivotal advancement in mechanical circulatory support, offering meaningful clinical benefits that extend beyond incremental pump performance. As technical maturation continues, the successful translation of these devices into routine care depends on coordinated strategies across product development, clinical evidence generation, supply chain resilience, and payer engagement. Stakeholders must recognize that device performance alone will not guarantee adoption; rather, integrated service models, demonstrable patient-centered outcomes, and pragmatic reimbursement strategies are equally critical.

Looking ahead, collaboration between manufacturers, clinicians, health systems, and payers will be central to realizing the full potential of maglev VADs. By committing to transparent post-market surveillance, targeted clinician training, and region-specific market access strategies, stakeholders can facilitate safe, equitable expansion of these therapies. The evolving policy environment and ongoing innovation in digital health present opportunities to redesign care pathways that improve patient experience while maintaining system sustainability. In sum, the path forward requires sustained evidence generation, adaptive operational planning, and a shared focus on delivering measurable clinical and economic value to patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fully MagLev Ventricular Assist Device Market, by Pump Placement

  • 8.1. Extracorporeal
  • 8.2. Intracorporeal
    • 8.2.1. Abdominal
    • 8.2.2. Thoracic
  • 8.3. Paracorporeal

9. Fully MagLev Ventricular Assist Device Market, by Age Group

  • 9.1. Adult
  • 9.2. Pediatric

10. Fully MagLev Ventricular Assist Device Market, by Insurance Coverage Type

  • 10.1. Private
  • 10.2. Public

11. Fully MagLev Ventricular Assist Device Market, by Application

  • 11.1. Bridge To Recovery
  • 11.2. Bridge To Transplant
    • 11.2.1. Long Term
    • 11.2.2. Short Term
  • 11.3. Destination Therapy

12. Fully MagLev Ventricular Assist Device Market, by End User

  • 12.1. Ambulatory Centres
  • 12.2. Cardiac Care Centers
  • 12.3. Hospitals
    • 12.3.1. Community
    • 12.3.2. Tertiary

13. Fully MagLev Ventricular Assist Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fully MagLev Ventricular Assist Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fully MagLev Ventricular Assist Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Fully MagLev Ventricular Assist Device Market

17. China Fully MagLev Ventricular Assist Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Berlin Heart GmbH
  • 18.7. BiVACOR Inc.
  • 18.8. CH Biomedical Co., Ltd.
  • 18.9. CorWave SA
  • 18.10. Evaheart Inc.
  • 18.11. Jarvik Heart Inc.
  • 18.12. Leviticus Cardio LLC
  • 18.13. Medtronic plc
  • 18.14. ReliantHeart Inc.
  • 18.15. Shenzhen Core Medical Technology Co., Ltd.
  • 18.16. Suzhou Tongxin Medical Devices Co., Ltd.
  • 18.17. SynCardia Systems LLC
  • 18.18. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTRACORPOREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTRACORPOREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTRACORPOREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THORACIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THORACIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THORACIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PARACORPOREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PARACORPOREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PARACORPOREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LONG TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LONG TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LONG TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SHORT TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SHORT TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY CENTRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY CENTRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COMMUNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COMMUNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COMMUNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY TERTIARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY TERTIARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY TERTIARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 179. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)